HOME >> MEDICINE >> NEWS
Four new us patents granted to Acrux for transdermal drug delivery

Acrux Limited (ASX: ACR), the Australian pharmaceutical company that specialises in products delivering therapeutic drugs through the skin, today announced that it has been granted four more US patents relating to its transdermal drug delivery technology. The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics (US patent number 6,916,486), hormones (6,923,983), anti-Parkinson's agents (6,929,801) and anti-emetics (6,916,487). These are "continuation in part" patents, related to Acrux's US patent number 6,818,226.

The new patents, which expire in February 2017, further extend the proprietary nature of Acrux's transdermal drug delivery technology for a number of products in the current pipeline. They provide protection for transdermal drug delivery systems, in the specific therapy areas, that consist of an effective amount of physiologically active agent (e.g. a therapeutic drug), a dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and a volatile liquid. Acrux now has six patents granted in the USA.

Acrux CEO and Managing Director, Dr Igor Gonda said: "These new US patents provide additional protection for our products in our core areas of interest. Our patenting activity is at the heart of our business strategy to develop and commercialise patient-preferred patent-protected healthcare products for valuable global markets."


'"/>

Contact: Igor Gonda
61-383-790-100
Research Australia
26-Sep-2005


Page: 1

Related medicine news :

1. REVLIMID(R) granted approval by FDA for treatment of multiple myeloma
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
4. Acrux completes enrollment in key phase 2 trial
5. Acrux and Oreganon further expand their collaboration
6. Acrux patent portfolio advances in USA
7. Acrux acquires rights to commercialise worlds first contraceptive spray
8. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
9. DAYTRANA (methylphenidate transdermal system) significant reduces ADHD symptoms
10. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD
11. Positive study results for methylphenidate transdermal system

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
Cached News: